소아에서의 Fluoroquinolones 사용: 최근 경향을 중심으로
The Use of Fluoroquinolones in Children: Recent Advances
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Fluoroquinolones have been widely used since the development of nalidixic acid because of the excellent spectrum of activity, superior tissue penetration, and convenient route of administration. Despite such advantages, the usage in children is limited by concerns of toxicity to cartilage, damage to joints in animal studies, and an increase in antibiotic resistance. However, pediatric use has been increasing under certain circumstances with no report of such adverse effects. Further study is required prior to recommendation for general use of fluoroquinolones in children. The careful administration of fluoroquinolones is recommended only in limited circumstances, such as failure of primary antibiotics and lack of alternative antibiotics. (Korean J Pediatr Infect Dis 2008;15:93-99)
Abstract
Fluoroquinolones have been widely used since the development of nalidixic acid because of the excellent spectrum of activity, superior tissue penetration, and convenient route of administration. Despite such advantages, the usage in children is limited by concerns of toxicity to cartilage, damage to joints in animal studies, and an increase in antibiotic resistance. However, pediatric use has been increasing under certain circumstances with no report of such adverse effects. Further study is required prior to recommendation for general use of fluoroquinolones in children. The careful administration of fluoroquinolones is recommended only in limited circumstances, such as failure of primary antibiotics and lack of alternative antibiotics. (Korean J Pediatr Infect Dis 2008;15:93-99)
참고문헌 (32)
- Gelone SP, "The newer fluoroquinolones", Infect Dis Clin North Am, 18, pp.691~716 (2004)
- Hooper DC, "New uses for new and old quinolones and the challenge of resistance", Clin Infect Dis, 30, pp.243~254 (2000)
- Ray GT, "Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa", Clin Infect Dis, 41, pp.441~449 (2005)
- MacDougall C, "Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals", Clin Infect Dis, 41, pp.435~440 (2005)
- Peltola H, "Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children", Antimicrob Agents Chemother, 36, pp.1086~1090 (1992)
- Rubio TT, "Pharmacokinetic disposition of sequential intravenous", oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation, 1997, pp.16, 112~117
- Lipman J, "Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?", Intensive Care Med, 28, pp.493~500 (2002)
- McDonald DF, "Usefulness of Nalidixic Acid in Treatment of Urinary Infection", Antimicrob Agents Chemother (Bethesda), 10, pp.628~631 (1964)
- Christ W, "Specific toxicologic aspects of the quinolones", Rev Infect Dis, 10(1), pp.S141~S146 (1988)
- Schluter G, "Ciprofloxacin: toxicologic evaluation of additional safety data", Am J Med, 87, pp.37S~39S (1989)
- Kato M, "Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo", Antimicrob Agents Chemother, 39, pp.1979~1983 (1995)
- Vormann J, "Gunther T, Merker H, et al. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity", Calcif Tissue Int, 61, pp.230~238 (1997)
- Burkhardt JE, "Quinolone arthropathy in animals versus children", Clin Infect Dis, 25, pp.1196~1204 (1997)
- Schaad UB, "Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients", Pediatr Infect Dis J, 11, pp.1047~1049 (1992)
- Schaad UB, "Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a threemonth course of ciprofloxacin", Pediatr Infect Dis J, 10, pp.723~729 (1991)
- Richard DA, "Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group", Pediatr Infect Dis J, 16, pp.572~578 (1997)
- Church DA, "Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime", tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group, 1997, pp.16, 97~105
- Pradhan KM, "Safety of ciprofloxacin therapy in children:magnetic resonance images, body fluid levels of fluoride and linear growth", Acta Paediatr, 84, pp.555~560 (1995)
- Chalumeau M, "Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France", Pediatrics, 111, pp.e714~e719 (2003)
- Drossou-Agakidou V, "Use of ciprofloxacin in neonatal sepsis:lack of adverse effects up to one year", Pediatr Infect Dis J, 23, pp.346~349 (2004)
- Hampel B, "Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report", Pediatr Infect Dis J, 16, pp.127~129 (1997)
- Mandell LA, "The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?", Clin Infect Dis, 35, pp.721~727 (2002)
- Gendrel D, "Fluoroquinolones in paediatrics: a risk for the patient or for the community?", The Lancet Infectious Diseases, 3, pp.537~546 (2003)
- Petrilli AS, "Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial", Med Pediatr Oncol, 34, pp.87~91 (2000)
- Thaver D, "Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)" (2005), Cochrane Database Syst Rev
- Moulin F, "Ciprofloxacin after clinical failure of beta-lactam antibiotics in children with salmonellosis", Arch Pediatr, 10, pp.608~614 (2003)
- Leibovitz E, "Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children", Pediatr Infect Dis J, 19, pp.1060~1067 (2000)
- Guerin PJ, "Case management of a multidrugresistant Shigella dysenteriae serotype 1 outbreak in a crisis context in Sierra Leone, 1999-2000", Trans R Soc Trop Med Hyg, 98, pp.635~643 (2004)
- Cizman M, "Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections", J Antimicrob Chemother, 47, pp.502~ (2001)
- Pichichero ME, "Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and", or AOM treatment failure, 2005, pp.41, 470~478
- Sabella C, "Management of otorrhea in infants and children", Pediatr Infect Dis J, 19, pp.1007~1008 (2000)
- Krcmery V, Jr, "Ciprofloxacin in treatment of nosocomial meningitis in neonates andin infants:report of 12 cases and review", Diagn Microbiol Infect Dis, 35, pp.75~80 (1999)